Krilogy Financial
FATE icon

Krilogy Financial’s Fate Therapeutics FATE Stock Holding History

Krilogy Financial’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-14,873
Closed -$40.2K – 1117
2026
Q2 		$40.2K Buy
14,873
+1,262
+9% +$2.34K ﹤0.01% 1042
2026
Q1 		$18.6K Buy
+13,611
New +$16.6K ﹤0.01% 970

Other funds holding FATE

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Krilogy Financial's FATE Position: Q3 2026 in Review

Krilogy Financial sold out of Fate Therapeutics (FATE) in Q3 2026, closing a stake of 14,873 shares — an estimated $40.2K sold.

Krilogy Financial first reported a position in FATE in Q1 2026 and held it in 2 quarters. The position peaked at $40.2K in Q2 2026. 101 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Krilogy Financial reported no remaining Fate Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Krilogy Financial sold 14,873 Fate Therapeutics shares in Q3 2026, an estimated $40.2K.
  • Krilogy Financial first reported a position in Fate Therapeutics in Q1 2026 and held it in 2 quarters.
  • Krilogy Financial's Fate Therapeutics position peaked at $40.2K in Q2 2026.
  • 101 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Krilogy Financial's 13F filing for Q3 2026, filed 13 Oct 2026.